Listed

Apyx Medical Corp

APYXNasdaqCIK 719135HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$13.9mRevenue, Q2 FY2026, three months to 2026-06-30$13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$13.9mRevenue, Q2 FY2026, three months to 2026-06-30$13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure+22.1% on a year earlier
  • Gross margin63.9%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $8.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Revenue: $13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure+1.6 pts on a year earlier
  • Operating margin−13.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Revenue: $13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure+9.6 pts on a year earlier
  • Net margin−23.4%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Revenue: $13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure+9.9 pts on a year earlier
  • Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
  • Free cash flow−$3.6mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001437749-26-026346. Derived: 6-month figure less the 3-month figure.Capital expenditure: $66.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001437749-26-026346. Derived: 6-month figure less the 3-month figure.Report this figure−137.4% on a year earlier

Last eight quarters

Full statements
Revenue$13.9mGross margin 63.9%
Free cash flow−$3.6m, Q2 FY2026
Apyx Medical Corp, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m11.5Revenue, Q3 FY2024, three months to 2024-09-30$11.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Report this figure14.2Revenue, Q4 FY2024, three months to 2024-12-31$14.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Report this figure9.4Revenue, Q1 FY2025, three months to 2025-03-31$9.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Report this figure11.4Revenue, Q2 FY2025, three months to 2025-06-30$11.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure12.9Revenue, Q3 FY2025, three months to 2025-09-30$12.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Report this figure19.2Revenue, Q4 FY2025, three months to 2025-12-31$19.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Report this figure12.5Revenue, Q1 FY2026, three months to 2026-03-31$12.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Report this figure13.9Revenue, Q2 FY2026, three months to 2026-06-30$13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure
Gross margin%60.5%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $7.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Revenue: $11.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Report this figure63.0%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $9.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Revenue: $14.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Report this figure60.1%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $5.7m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Revenue: $9.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Report this figure62.3%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $7.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Revenue: $11.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure64.4%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $8.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Revenue: $12.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Report this figure62.6%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $12.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Revenue: $19.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Report this figure63.5%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $7.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Revenue: $12.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Report this figure63.9%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $8.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Revenue: $13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure
Operating margin%(31.6%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Revenue: $11.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Report this figure(21.4%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$3.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Revenue: $14.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Report this figure(32.4%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Revenue: $9.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Report this figure(22.6%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Revenue: $11.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure(6.5%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$832.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Revenue: $12.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Report this figure0.1%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $11.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Revenue: $19.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Report this figure(7.3%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$911.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Revenue: $12.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Report this figure(13.0%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Revenue: $13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure
Net margin%(40.9%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$4.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Revenue: $11.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Report this figure(32.5%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$4.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Revenue: $14.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Report this figure(44.0%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$4.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Revenue: $9.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Report this figure(33.2%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Revenue: $11.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure(15.4%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Revenue: $12.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001437749-25-033499.Report this figure(6.8%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Revenue: $19.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Report this figure(16.9%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Revenue: $12.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Report this figure(23.4%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Revenue: $13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001437749-26-026346.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m(4.6)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001437749-25-033499. Derived: 9-month figure less the 6-month figure.Capital expenditure: $153.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001437749-25-033499. Derived: 9-month figure less the 6-month figure.Report this figure(3.2)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Capital expenditure: $245.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Report this figure(0.8)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$702.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Capital expenditure: $55.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Report this figure(1.5)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001437749-26-026346. Derived: 6-month figure less the 3-month figure.Capital expenditure: $265.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001437749-26-026346. Derived: 6-month figure less the 3-month figure.Report this figure(4.1)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001437749-25-033499. Derived: 9-month figure less the 6-month figure.Capital expenditure: $519.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001437749-25-033499. Derived: 9-month figure less the 6-month figure.Report this figure(2.8)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Capital expenditure: $275.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-10, accession 0001437749-26-007471. Derived: 12-month figure less the 9-month figure.Report this figure(0.6)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$572.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Capital expenditure: $60.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001437749-26-015652.Report this figure(3.6)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001437749-26-026346. Derived: 6-month figure less the 3-month figure.Capital expenditure: $66.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001437749-26-026346. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$52.8mGross margin 62.5%
Diluted EPS−$0.54, FY2023
Free cash flow−$9.1m, FY2025
Apyx Medical Corp, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m48.5Revenue, FY2021, twelve months to 2021-12-31$48.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-16, accession 0000719135-23-000018.Report this figure44.5Revenue, FY2022, twelve months to 2022-12-31$44.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-21, accession 0000719135-24-000016.Report this figure52.3Revenue, FY2023, twelve months to 2023-12-31$52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-13, accession 0001437749-25-007521.Report this figure48.1Revenue, FY2024, twelve months to 2024-12-31$48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471.Report this figure52.8Revenue, FY2025, twelve months to 2025-12-31$52.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471.Report this figure
Gross margin%69.3%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $33.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2023-03-16, accession 0000719135-23-000018.Revenue: $48.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-16, accession 0000719135-23-000018.Report this figure65.4%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $29.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-21, accession 0000719135-24-000016.Revenue: $44.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-21, accession 0000719135-24-000016.Report this figure64.5%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $33.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-03-13, accession 0001437749-25-007521.Revenue: $52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-13, accession 0001437749-25-007521.Report this figure61.0%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $29.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-10, accession 0001437749-26-007471.Revenue: $48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471.Report this figure62.5%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $33.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-10, accession 0001437749-26-007471.Revenue: $52.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471.Report this figure
Operating margin%(29.8%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$14.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-16, accession 0000719135-23-000018.Revenue: $48.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-16, accession 0000719135-23-000018.Report this figure(52.9%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$23.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-21, accession 0000719135-24-000016.Revenue: $44.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-21, accession 0000719135-24-000016.Report this figure(33.0%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$17.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-13, accession 0001437749-25-007521.Revenue: $52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-13, accession 0001437749-25-007521.Report this figure(39.2%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$18.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001437749-26-007471.Revenue: $48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471.Report this figure(12.2%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001437749-26-007471.Revenue: $52.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471.Report this figure
Net margin%(31.3%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$15.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-16, accession 0000719135-23-000018.Revenue: $48.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-16, accession 0000719135-23-000018.Report this figure(52.1%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$23.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-21, accession 0000719135-24-000016.Revenue: $44.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-21, accession 0000719135-24-000016.Report this figure(35.7%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$18.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-13, accession 0001437749-25-007521.Revenue: $52.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-13, accession 0001437749-25-007521.Report this figure(48.8%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$23.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001437749-26-007471.Revenue: $48.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471.Report this figure(21.2%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$11.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001437749-26-007471.Revenue: $52.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001437749-26-007471.Report this figure
Diluted EPS$ per share(0.44)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-16, accession 0000719135-23-000018.Report this figure(0.67)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-21, accession 0000719135-24-000016.Report this figure(0.54)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-21, accession 0000719135-24-000016.Report this figurenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m(11.2)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$10.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-16, accession 0000719135-23-000018.Capital expenditure: $723.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-16, accession 0000719135-23-000018.Report this figure(21.3)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$20.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-21, accession 0000719135-24-000016.Capital expenditure: $1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-21, accession 0000719135-24-000016.Report this figure(5.8)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-13, accession 0001437749-25-007521.Capital expenditure: $533.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-13, accession 0001437749-25-007521.Report this figure(18.8)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$18.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001437749-26-007471.Capital expenditure: $722.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-10, accession 0001437749-26-007471.Report this figure(9.1)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$8.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001437749-26-007471.Capital expenditure: $1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-10, accession 0001437749-26-007471.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Apyx Medical Corp
FundQuarter endedReported valueSharesPut or callChange on the quarter before
ROYCE & ASSOCIATES LP2026-06-30$14.7m3,274,064Added+662,840
Nantahala Capital Management, LLC2026-06-30$14.7m3,270,248Reduced−170,056
Nantahala Capital Management, LLC2026-06-30$14.7m3,270,248Reduced−170,056
Archon Capital Management LLC2026-06-30$11.9m2,644,717Reduced−146,206
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$6.9m1,534,847Reduced−20,425
ESSEX INVESTMENT MANAGEMENT CO LLC2026-06-30$5.1m1,136,630Added+235,232
AIGH Capital Management LLC2026-06-30$5.1m1,128,343Added+23,373
Silverberg Bernstein Capital Management LLC2026-06-30$4.7m1,039,641Reduced−1,429
COMMONWEALTH EQUITY SERVICES, LLC2026-06-30$2.9m649,061Unchanged
HORIZON KINETICS ASSET MANAGEMENT LLC2026-06-30$2.6m585,000Reduced−30,000

Recent filings

All 688 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Apyx Medical Corp, recent filings
FiledFormWhat it isAccession number
2026-09-2916:19 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001437749-26-031468
2026-08-0716:00 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001493152-26-036557
2026-08-0617:01 ET10-QQuarterly reportPeriod 2026-06-300001437749-26-026346
2026-08-0616:09 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-026262
2026-07-2417:18 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001493152-26-034619
2026-06-2616:13 ETDEF 14AProxy statementPeriod 2025-12-310001437749-26-021840
2026-06-1716:05 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001493152-26-029081
2026-05-2116:23 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001437749-26-018098
2026-05-1408:05 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001437749-26-016885
2026-05-1108:07 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001437749-26-016000

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 10, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
719135
Tickers
APYX
Exchange
Nasdaq
SIC code
3841 Surgical & Medical Instruments & Apparatus
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
BOVIE MEDICAL CORP (to 2019-01-02); BOVIE MEDICAL Corp (to 2019-01-02); AN CON GENETICS INC (to 1999-01-13)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:22 ET. Listed shows no prices and gives no investment advice.